EMA adopts new policy on merging and splitting paediatric investigation plans
This article was originally published in SRA
The European Medicines Agency has issued a new policy on paediatric investigation plans to address the problems that companies face when they make changes to their drug development plans midstream1,2.
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.